HER2-Low Breast Cancer: Where Are We?

• Published in: Breast care (Basel, Switzerland) Vol. 17; no. 6; pp. 533 - 545
• Main Authors: Molinelli, Chiara, Jacobs, Flavia, Marchiò, Caterina, Pitto, Francesca, Cosso, Maurizio, Spinaci, Stefano, de Azambuja, Evandro, Schettini, Francesco, Agostinetto, Elisa, Lambertini, Matteo
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.12.2022
• Subjects: Review; Review Article; Trastuzumab deruxtecan; HER2-low; Breast cancer
• ISSN: 1661-3791; 1661-3805
• DOI: 10.1159/000527391

Background: Breast cancer is traditionally classified into three clinical subtypes based on hormone receptor and HER2 status (i.e., luminal-like, HER2-positive, and triple negative). Each subtype has distinct clinical-pathological and molecular characteristics and requires tailored treatments. Recent research efforts have been focusing on a new classification, identifying the so-called “HER2-low” category, including tumors characterized by a low level of HER2 expression (immunohistochemistry score 1+ or 2+ without in situ hybridization amplification). Emerging evidence shows that patients with HER2-low tumors can derive benefit from selected anti-HER2 therapies. This represents a major advancement in the field of breast oncology, where a broader proportion of patients with breast cancer can ultimately benefit from new effective targeted treatment strategies. Summary: The antibody-drug conjugate trastuzumab deruxtecan has proven impressive efficacy in patients with HER2-low breast cancer, and several other drugs are currently under investigation in this subset of patients. Additional investigation is needed to address open issues that exist in this field, including appropriate pathological assessment of HER2-low status, clarification of its prognostic implications, and global access to newly approved drugs. Key Message: Our review aims to summarize the available evidence regarding HER2-low breast cancer, illustrating the current challenges that are being addressed and the future perspectives in this exciting new field.